H&H International Holdings (SEHK: 01112) saw its shares rise nearly 9% in morning trading, following a significant surge of almost 19% in the previous session. As of the latest update, the stock is up 8.84%, trading at HK$14.65 with a turnover of HK$55.11 million.

The company recently announced that for the six months ended June 30, 2026, on a comparable basis, the group's total revenue achieved double-digit growth compared to the same period last year. This growth was primarily driven by expansion across all business segments, including Adult Nutrition and Care, Baby and Child Nutrition and Care, and Pet Nutrition and Care. During the period, adjusted comparable net profit is expected to increase by over 100% year-on-year, while reported net profit attributable to shareholders is projected to surge by over 700% year-on-year due to a low base effect.

Analyst Commentary

Huatai Securities noted that in the first half of 2026, the company's BNC business revenue recorded high double-digit year-on-year growth, with infant formula growing by over 50%. The PNC business revenue in the same period saw mid to high single-digit year-on-year growth, mainly attributed to accelerated growth in the high-margin pet nutrition category and channel expansion in North America. Looking ahead, the company is expected to increase marketing investment in the second half of the year to support the promotion of new Biostime HMO products and new Swisse products. The direction of improving operating leverage in 2026 remains unchanged, with efforts to accelerate debt reduction and enhance financial health, leading the brokerage to maintain its "Buy" rating.